Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Mar Drugs ; 18(7)2020 Jul 21.
Article in English | MEDLINE | ID: mdl-32708077

ABSTRACT

Emerging literature suggests that after a stroke, the peri-infarct region exhibits dynamic changes in excitability. In rodent stroke models, treatments that enhance excitability in the peri-infarct cerebral cortex promote motor recovery. This increase in cortical excitability and plasticity is opposed by increases in tonic GABAergic inhibition in the peri-infarct zone beginning three days after a stroke in a mouse model. Maintenance of a favorable excitatory-inhibitory balance promoting cerebrocortical excitability could potentially improve recovery. Brevetoxin-2 (PbTx-2) is a voltage-gated sodium channel (VGSC) gating modifier that increases intracellular sodium ([Na+]i), upregulates N-methyl-D-aspartate receptor (NMDAR) channel activity and engages downstream calcium (Ca2+) signaling pathways. In immature cerebrocortical neurons, PbTx-2 promoted neuronal structural plasticity by increasing neurite outgrowth, dendritogenesis and synaptogenesis. We hypothesized that PbTx-2 may promote excitability and structural remodeling in the peri-infarct region, leading to improved functional outcomes following a stroke. We tested this hypothesis using epicortical application of PbTx-2 after a photothrombotic stroke in mice. We show that PbTx-2 enhanced the dendritic arborization and synapse density of cortical layer V pyramidal neurons in the peri-infarct cortex. PbTx-2 also produced a robust improvement of motor recovery. These results suggest a novel pharmacologic approach to mimic activity-dependent recovery from stroke.


Subject(s)
Cerebral Cortex/drug effects , Excitatory Amino Acid Agonists/administration & dosage , Marine Toxins/administration & dosage , Motor Activity/drug effects , Neuronal Plasticity/drug effects , Oxocins/administration & dosage , Thrombotic Stroke/drug therapy , Animals , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Cerebral Cortex/physiopathology , Disease Models, Animal , Injections , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Mice, Transgenic , Recovery of Function , Thrombotic Stroke/metabolism , Thrombotic Stroke/pathology , Thrombotic Stroke/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL